Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J0EM
|
||||
| Former ID |
DIB003170
|
||||
| Drug Name |
Virexxa
|
||||
| Indication | Endometrial cancer [ICD9: 182; ICD10:C54.1] | Phase 2 | [1] | ||
| Company |
Pharmsynthez ZAO
|
||||
| Target and Pathway | |||||
| Target(s) | Progesterone receptor | Target Info | Inducer | [2] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Progesterone-mediated oocyte maturation | |||||
| Pathway Interaction Database | Cellular roles of Anthrax toxin | ||||
| Reactome | Nuclear signaling by ERBB4 | ||||
| Nuclear Receptor transcription pathway | |||||
| WikiPathways | Ovarian Infertility Genes | ||||
| Signaling by ERBB4 | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02064725) Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.